Form 4: Avid Bioservices VP, General Counsel Mark Ziebell Disposes of Shares and Options in Merger

Mark Ziebell, VP and General Counsel of Avid Bioservices, reports the disposal of common stock, stock options, restricted stock units, and performance stock units due to the merger with Space Mergerco, Inc.

Summary

• Mark Ziebell, the VP and General Counsel of Avid Bioservices, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports transactions occurring on February 5, 2025, related to the merger of Avid Bioservices with Space Mergerco, Inc.
• Ziebell disposed of 66,799 shares of common stock, which were converted into the right to receive $12.50 per share as part of the merger agreement.
• He also disposed of various stock options, restricted stock units (RSUs), and performance stock units (PSUs), which were converted into cash payments based on the merger consideration.
• The cash payments for vested options were calculated as the difference between the merger consideration ($12.50) and the exercise price, multiplied by the number of shares.
• Both vested and unvested RSUs and PSUs were converted into the right to receive $12.50 per share.
• Following these transactions, Ziebell's direct ownership includes 174,859 stock options with an exercise price of $9.17, 153,430 stock options with an exercise price of $3.5007, 55,310 stock options with an exercise price of $6.07, and 0 stock options with an exercise price of $6.95.
• Ziebell also directly owns 51,413 restricted stock units and 108,579 performance stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports the execution of a merger agreement and the resulting transactions. There are no explicit positive or negative implications for the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a common scenario where a merger or acquisition leads to changes in the ownership structure and compensation arrangements for company executives. The conversion of stock and equity-based compensation into cash is typical in such transactions.

Comparison to Industry Standards

• Mergers and acquisitions in the biopharmaceutical industry often involve similar arrangements for executives, where stock options and restricted stock units are cashed out or converted into equivalent value based on the acquisition price.
• The $12.50 per share merger consideration would need to be compared to other recent acquisitions in the CDMO (Contract Development and Manufacturing Organization) sector to assess its relative value.
• Comparable companies in the CDMO space include Catalent, Thermo Fisher Scientific, and Lonza, and their acquisition multiples (e.g., price-to-sales, price-to-earnings) could be used as benchmarks.

Stakeholder Impact

• Shareholders received $12.50 per share as part of the merger agreement.
• Employees with stock options, RSUs, and PSUs received cash payments based on the merger consideration.

Key Dates

Keywords

Avid Bioservices, Mark Ziebell, Form 4, Merger, Space Mergerco, Beneficial Ownership, Stock Options, Restricted Stock Units, Performance Stock Units, CDMO